UChicago Medicine physician-scientists aimed to find out how the immune systems of children with a type of cancer called neuroblastoma respond to tumors. The answer to this question could help guide the treatment of pediatric patients.
A newly developed immunotherapy that simultaneously uses modified immune-fighting cells to home in on and attack two antigens, or foreign substances, on cancer cells was highly effective in mice implanted with human neuroblastoma tissue.
Neuroblastoma is the deadliest and most common solid cancer in young children the world over, accounting for 15 per cent of all childhood cancer deaths. But Australian researchers are taking the first steps to find the cause and better treatments for this devastating disease which affects children under the age of five.
Un nuevo estudio de los investigadores de Mayo Clinic identificó que un gen de inestabilidad cromosómica, el USP24, está a menudo ausente en los pacientes pediátricos con neuroblastoma (tipo agresivo de cáncer cerebral en niños). El resultado ofrece una perspectiva importante sobre el desarrollo de esta enfermedad.
A new study by Mayo Clinic researchers has identified that a chromosome instability gene, USP24, is frequently missing in pediatric patients with neuroblastoma, an aggressive form of childhood cancer. The finding provides important insight into the development of this disease. The study is published in Cancer Research, the journal of the American Association for Cancer Research.
Researchers have used insight from a comprehensive genomic analysis of neuroblastoma to learn about the process driving one of the most common childhood solid tumors.
Mount Sinai researchers have identified a targeted therapy for adolescent patients with neuroblastoma, a deadly pediatric nerve cancer, who would otherwise have no treatment options, according to a study published in October in Cancer Cell.
Roswell Park’s Dr. Clare Twist led an effort to develop and validate a new treatment algorithm for infants and children with neuroblastoma. In a new study in the Journal of Clinical Oncology, the team reports that many patients can safely receive less extensive therapy.